GlycoMark® Testing for Glycemic Control

Medicare does not cover GlycoMark® (1,5‑anhydroglucitol) testing — it is considered not reasonable or necessary for diabetes management or prevention of complications, including use to detect hyperglycemic excursions in patients with A1C <8%. The policy cites poor/insufficient evidence and lack of prospective data or guidelines to support clinical utility, and no documentation or coverage requirements apply because the test is non‑covered.

"This is a non-coverage policy for the GlycoMark® assay (aka 1,5-anhydroglucitol [1,5-AG]; developed by Nippon Kayaku, Co."

Sign up to see full coverage criteria, indications, and limitations.